These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 33162769)

  • 61. Role of lipids and lipid signaling in the development of cannabinoid tolerance.
    Martin BR
    Life Sci; 2005 Aug; 77(14):1543-58. PubMed ID: 15949820
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cannabis and psychiatric disorders: it is not only addiction.
    Leweke FM; Koethe D
    Addict Biol; 2008 Jun; 13(2):264-75. PubMed ID: 18482435
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phytocannabinoids as novel therapeutic agents in CNS disorders.
    Hill AJ; Williams CM; Whalley BJ; Stephens GJ
    Pharmacol Ther; 2012 Jan; 133(1):79-97. PubMed ID: 21924288
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Modulating the endocannabinoid system in human health and disease--successes and failures.
    Pacher P; Kunos G
    FEBS J; 2013 May; 280(9):1918-43. PubMed ID: 23551849
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Simultaneous Assessment of Serum Levels and Pharmacologic Effects of Cannabinoids on Endocannabinoids and
    Couttas TA; Boost C; Pahlisch F; Sykorova EB; Leweke JE; Koethe D; Endepols H; Rohleder C; Leweke FM
    Cannabis Cannabinoid Res; 2023 Aug; 8(4):657-669. PubMed ID: 35580134
    [No Abstract]   [Full Text] [Related]  

  • 66. [The role of endocannabinoid system in physiological and pathological processes in the eye].
    Nadolska K; Goś R
    Klin Oczna; 2008; 110(10-12):392-6. PubMed ID: 19195174
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
    Rosenberg EC; Patra PH; Whalley BJ
    Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cannabinoids in depressive disorders.
    Poleszak E; Wośko S; Sławińska K; Szopa A; Wróbel A; Serefko A
    Life Sci; 2018 Nov; 213():18-24. PubMed ID: 30290188
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Role of cannabinoids in the development of fatty liver (steatosis).
    Purohit V; Rapaka R; Shurtleff D
    AAPS J; 2010 Jun; 12(2):233-7. PubMed ID: 20204561
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The endocannabinoid system and its therapeutic exploitation.
    Di Marzo V; Bifulco M; De Petrocellis L
    Nat Rev Drug Discov; 2004 Sep; 3(9):771-84. PubMed ID: 15340387
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Synaptic Interactions of Alcohol and the Endogenous Cannabinoid System.
    Wolfe SA; Vozella V; Roberto M
    Alcohol Res; 2022; 42(1):03. PubMed ID: 35223337
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis.
    Jacobson MR; Watts JJ; Boileau I; Tong J; Mizrahi R
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):330-348. PubMed ID: 30635160
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Three of a Kind: Control of the Expression of Liver-Expressed Antimicrobial Peptide 2 (LEAP2) by the Endocannabinoidome and the Gut Microbiome.
    Shen M; Manca C; Suriano F; Nallabelli N; Pechereau F; Allam-Ndoul B; Iannotti FA; Flamand N; Veilleux A; Cani PD; Silvestri C; Di Marzo V
    Molecules; 2021 Dec; 27(1):. PubMed ID: 35011234
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions
.
    Spanagel R
    Dialogues Clin Neurosci; 2020 Sep; 22(3):241-250. PubMed ID: 33162767
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cannabinoids and the gut: new developments and emerging concepts.
    Izzo AA; Sharkey KA
    Pharmacol Ther; 2010 Apr; 126(1):21-38. PubMed ID: 20117132
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Psychiatric Disorders and Cannabinoid Receptors.
    Joshi N; Onaivi ES
    Adv Exp Med Biol; 2021; 1264():131-153. PubMed ID: 33332008
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cannabinoid ligand-receptor signaling in the mouse uterus.
    Das SK; Paria BC; Chakraborty I; Dey SK
    Proc Natl Acad Sci U S A; 1995 May; 92(10):4332-6. PubMed ID: 7753807
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.
    Marco EM; García-Gutiérrez MS; Bermúdez-Silva FJ; Moreira FA; Guimarães F; Manzanares J; Viveros MP
    Front Behav Neurosci; 2011; 5():63. PubMed ID: 22007164
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration.
    Basavarajappa BS; Nixon RA; Arancio O
    Mini Rev Med Chem; 2009 Apr; 9(4):448-62. PubMed ID: 19356123
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Endocannabinoids in the central nervous system].
    Venance L; Maldonado R; Manzoni O
    Med Sci (Paris); 2004 Jan; 20(1):45-53. PubMed ID: 14770363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.